| Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer M Georganaki, L van Hooren, A Dimberg Frontiers in immunology 9, 427486, 2018 | 127 | 2018 |
| Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer L van Hooren, LC Sandin, I Moskalev, P Ellmark, A Dimberg, P Black, ... European journal of immunology 47 (2), 385-393, 2017 | 74 | 2017 |
| Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma L van Hooren, A Vaccaro, M Ramachandran, K Vazaios, S Libard, ... Nature Communications 12 (1), 4127, 2021 | 70 | 2021 |
| Platelet-specific PDGFB ablation impairs tumor vessel integrity and promotes metastasis Y Zhang, J Cedervall, A Hamidi, M Herre, K Viitaniemi, G D'Amico, Z Miao, ... Cancer Research 80 (16), 3345-3358, 2020 | 43 | 2020 |
| Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment L van Hooren, M Georganaki, H Huang, SM Mangsbo, A Dimberg Oncotarget 7 (31), 50277, 2016 | 41 | 2016 |
| Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy M Georganaki, M Ramachandran, S Tuit, NG Núñez, A Karampatzakis, ... Oncoimmunology 9 (1), 1730538, 2020 | 28 | 2020 |
| CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma L van Hooren, SM Handgraaf, DJ Kloosterman, E Karimi, LWHG van Mil, ... Nature Cancer 4 (5), 665-681, 2023 | 19 | 2023 |
| Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma M Ramachandran, A Vaccaro, T van de Walle, M Georganaki, R Lugano, ... Cancer Cell 41 (6), 1134-1151. e10, 2023 | 16 | 2023 |
| Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden J Femel, L van Hooren, M Herre, J Cedervall, F Saupe, EJM Huijbers, ... Cancer Immunology, Immunotherapy 71 (8), 2029-2040, 2022 | 15 | 2022 |
| ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma H Huang, M Georganaki, LL Conze, B Laviña, L van Hooren, K Vemuri, ... Neuro-oncology 24 (3), 398-411, 2022 | 10 | 2022 |
| Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations IK Kerzeli, M Lord, M Doroszko, R Elgendy, A Chourlia, I Stepanek, ... Plos one 16 (7), e0253178, 2021 | 5 | 2021 |
| Correction to: Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden J Femel, L van Hooren, M Herre, J Cedervall, F Saupe, EJM Huijbers, ... Cancer Immunology, Immunotherapy 71 (10), 2581-2581, 2022 | 2 | 2022 |
| Agonistic CD40 antibody therapy induces tertiary lymphoid structures but impairs the response to immune checkpoint blockade in glioma L van Hooren, A Vaccaro, M Ramachandran, K Vazaios, S Libard, ... bioRxiv, 2021.01. 05.425377, 2021 | 2 | 2021 |
| Abstract B103: Intralesional administration of CTLA-4 blocking monoclonal antibodies as a means to optimize bladder cancer therapy L Hooren, L Sandin, I Moskalev, P Ellmark, A Dimberg, P Black, ... Cancer Immunology Research 4 (11_Supplement), B103-B103, 2016 | 1 | 2016 |
| CD93 maintains endothelial barrier function and limits metastatic dissemination K Vemuri, B de Alves Pereira, P Fuenzalida, Y Subashi, S Barbera, ... JCI insight 9 (7), 2024 | | 2024 |
| CD93 limits VEGFR2 activation and preserves endothelial barrier function in metastatic cancer K Vemuri, B de Alves Pereira, P Fuenzalida, Y Subashi, L van Hooren, ... | | 2022 |
| Development and characterization of a novel autochthonous semi-spontaneous bladder cancer model by pathological evaluation, single cell sequencing and proteomic profiling IK Kerzeli, M Lord, I Stepanek, A Chourlia, E Larsson, R Elgendy, ... Urologic Oncology: Seminars and Original Investigations 38 (12), 896, 2020 | | 2020 |
| Abstract A128: Tumor endothelial cells say IDO to CD40-stimulating immunotherapy A Dimberg, A Karampatzakis, S Tuit, M Ramachandran, G Fotaki, ... Cancer Immunology Research 7 (2_Supplement), A128-A128, 2019 | | 2019 |
| Abstract A159: Agonistic CD40 antibody therapy induces formation of tertiary lymphoid structures in glioma and inhibits the response to immune-checkpoint blockade L Hooren, A Vaccaro, M Georganaki, M Ramachandran, H Huang, J Lau, ... Cancer Immunology Research 7 (2_Supplement), A159-A159, 2019 | | 2019 |
| Antibody-based immunotherapy of cancer: From optimization to novel approaches L van Hooren Acta Universitatis Upsaliensis, 2018 | | 2018 |
